Again, can we go all the way until we reach the PARADIGME readout and 1 day before we run out of cash? I don’t think that it will be a very intelligent thing, but we are committed to making sure that our cash expenses will allow us for that if worse was to come.
So this is what we have. So the first 3 programs, remember, they are ongoing, they are fully funded on this idea of getting to the PARADIGME data. So first, of course, is PARADIGME, our pivotal Phase IIb in third-line follicular lymphoma on patients that are relapse, refractory to anti-CD20.
Then we have our second line follicular lymphoma, Archer-1, the Phase Ib trial, and Lisa will cover. Remember we just announced that the trial had started as promised and that we have recruited our first patient.
Then we have our relapse remitting DLBCL on patients that are not eligible to stem cell transplantation. Again, there’s nothing that we’re going to be telling about this program today because there are no news, which is good news. The trial keeps enrolling. Remember, we announced at the last – end of August that the first 2 cohorts, we were safe and that we were allowed to move into the third cohort, which is being recruited.
And then we have, as I mentioned, other programs that we could do with Betalutin. We have Humalutin there. And as you know, we have just announced, would be presented at ASH, that there’s a program that we have in combination with Orano Med, it’s a – which is our humanized anti-CD37. So the same antibody as we were – we would use in Humalutin in combination with lead-212. That eventually could be developed for CLL.
Very importantly, if you look at the preclinical data, there’s 2 things to say: one, lead-212 has already been tested in clinical trials by Orano Med in solid tumors, it’s a safe payload at least on that trial; second, the preclinical data shows that 90% to 100% of the mice, and it’s mice, it’s not humans, were alive after being tested with this combination. So it’s a promising alternative. Again, for the time being, we’re just deciding how we should be developing this going forward.
And I want to make one – we decided to make this extra slide because I think that we are in a very, very exciting field. And these ideas of (inaudible), so sometimes you are against the market, sometimes you are with the market.
But there’s a huge amount of companies that are putting a lot of effort in radio pharmaceuticals. And the fact that a few years ago, these came very strong and then it fade away because the products were not a commercial success. What we’re seeing now is second-generation products coming into the market, and that commercial success happening. Not only commercial success, but that of course immediately makes big pharma companies to be very attentive to these opportunities.
So I’m sorry that they are probably not in the right order, but there’s now a few products that are on the market. Of course, here, everyone knows Xofigo, which is the Algeta product that was acquired by Bayer. But that was – this is a product that 2017, so last year, reported over EUR 400 million in sales with a 23% growth over the previous year. So people that were very doubtful that you could be successful commercially with a radiopharmaceutical product, they’re proving them wrong.
Very importantly, you know the second one, one at the top, Lutathera, this was a product that AAA developed and that Novartis acquired for $3.9 billion in 2018. So earlier this year, they’ve launched the product in the fourth quarter. They’ve reported $50 million already in the first – in the last quarter of 2017. And if you look at the R&D presentation that Novartis made earlier this week, they developed a lot of time to how they see the potential for this product.
They were so happy with this acquisition that, very recently, Novartis also acquired, as announced, their intention to acquire Endocyte, for, again, a $2.1 billion acquisition. They have this product, again, with lutetium-177. So Novartis seems to like lutetium-177. We think, as we’ve been saying for a long time, that we think that is a great payload, and they have announced their intention to acquire this. Novartis is really focused on solid tumors if you look at the way they’re doing.
Relevant quote fra Bravo
, det er ingenting som er sagt om hva man skal bruke noen eventuelle ferske penger til. Det er feil å konstantere at Humalutin startes igjen ved første innlassing av nye penger for det har aldri blitt sagt.
